Anthera Pharmaceuticals (ANTH) Earning Somewhat Favorable News Coverage, Analysis Finds

Media headlines about Anthera Pharmaceuticals (NASDAQ:ANTH) have trended somewhat positive this week, Accern reports. The research group identifies negative and positive media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Anthera Pharmaceuticals earned a news impact score of 0.19 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 46.6413799003588 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

These are some of the news stories that may have effected Accern Sentiment’s analysis:

Shares of Anthera Pharmaceuticals (NASDAQ ANTH) traded down $0.03 during trading on Friday, hitting $1.69. 487,872 shares of the company were exchanged, compared to its average volume of 776,009. The firm has a market capitalization of $23.41, a price-to-earnings ratio of -0.31 and a beta of 2.67. Anthera Pharmaceuticals has a fifty-two week low of $1.20 and a fifty-two week high of $6.24.

A number of analysts recently weighed in on ANTH shares. Zacks Investment Research raised shares of Anthera Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.75 price target for the company in a report on Tuesday, February 13th. ValuEngine raised shares of Anthera Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Sunday, December 31st.

ILLEGAL ACTIVITY NOTICE: This piece of content was first published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece of content can be accessed at

About Anthera Pharmaceuticals

Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.

Insider Buying and Selling by Quarter for Anthera Pharmaceuticals (NASDAQ:ANTH)

Receive News & Ratings for Anthera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply